Candel Therapeutics (CADL) Gains from Investment Securities (2020 - 2025)
Candel Therapeutics recorded quarterly Gains from Investment Securities of $13.5 million in Q4 2025, up 1279.67% quarter-over-quarter from -$1.1 million in Q3 2025, and up 131.81% year-over-year from $5.8 million in Q4 2024.
Candel Therapeutics' Gains from Investment Securities history runs 6 years deep, the most recent figure standing at $13.5 million for Q4 2025.
- In Q4 2025, Gains from Investment Securities rose 131.81% year-over-year to $13.5 million; the TTM figure through Dec 2025 stood at $12.5 million (up 169.06% YoY), while the FY2025 annual figure was $2.2 million, down 51.28% from the prior year.
- Gains from Investment Securities came in at $13.5 million for Q4 2025 at Candel Therapeutics, up from -$1.1 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $13.5 million in Q4 2025 to a low of -$5.7 million in Q2 2025.
- A 5-year average of $2.6 million and a median of $1.6 million in 2023 frame the typical range for Gains from Investment Securities.
- Across the five-year window, Gains from Investment Securities sank 274500.0% in 2022 and jumped 23237.86% in 2025, its largest moves.
- Candel Therapeutics' Gains from Investment Securities stood at $1000.0 in 2021, then tumbled by 274500.0% to -$2.7 million in 2022, then surged by 157.22% to $1.6 million in 2023, then jumped by 271.46% to $5.8 million in 2024, then surged by 131.81% to $13.5 million in 2025.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered $13.5 million, -$1.1 million, and -$5.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Candel Therapeutics | 449.62 Mn | 449.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 13.52 Mn |
| Dec 31, 2025 | 13.52 Mn |
| Sep 30, 2025 | -1.15 Mn |
| Sep 30, 2025 | -1.15 Mn |
| Jun 30, 2025 | -5.69 Mn |
| Jun 30, 2025 | -5.69 Mn |
| Mar 31, 2025 | 1.62 Mn |
| Mar 31, 2025 | 1.62 Mn |
| Dec 31, 2024 | 5.83 Mn |
| Dec 31, 2024 | 5.83 Mn |
| Sep 30, 2024 | 535,917.00 |
| Sep 30, 2024 | 535,917.00 |
| Jun 30, 2024 | 4.68 Mn |
| Jun 30, 2024 | 4.68 Mn |
| Mar 31, 2024 | -7,000.00 |
| Mar 31, 2024 | -7,000.00 |
| Dec 31, 2023 | 1.57 Mn |
| Dec 31, 2023 | 1.57 Mn |
| Sep 30, 2023 | 6.06 Mn |
| Sep 30, 2023 | 6.06 Mn |
| Jun 30, 2023 | 6.42 Mn |
| Jun 30, 2023 | 6.42 Mn |
| Mar 31, 2023 | 61,000.00 |
| Mar 31, 2023 | 61,000.00 |
| Dec 31, 2022 | -2.74 Mn |
| Dec 31, 2022 | -2.74 Mn |
| Sep 30, 2022 | 1.33 Mn |
| Sep 30, 2022 | 1.33 Mn |
| Jun 30, 2022 | 5.65 Mn |
| Jun 30, 2022 | 5.65 Mn |
| Mar 31, 2022 | 1.98 Mn |
| Mar 31, 2022 | 1.98 Mn |
| Dec 31, 2021 | 1,000.00 |
| Dec 31, 2021 | 1,000.00 |
| Sep 30, 2021 | 8.25 Mn |
| Sep 30, 2021 | 8.25 Mn |
| Jun 30, 2021 | 4.61 Mn |
| Jun 30, 2021 | 4.61 Mn |
| Mar 31, 2021 | 277,000.00 |
| Mar 31, 2021 | 277,000.00 |
| Dec 31, 2020 | 31,000.00 |
| Dec 31, 2020 | 31,000.00 |
| Jun 30, 2020 | 507,000.00 |
| Jun 30, 2020 | 507,000.00 |